Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / Steve N. Slilaty / Sunshine Biopharma

Steve N. Slilaty & Sunshine Biopharma

1 shared events · Importance 3 · Last updated Jun 25, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
63
Regulatory
Sunshine Biopharma Anastrozole Canadian Approval
Steve N. Slilaty: Steve N. Slilaty, CEO of Sunshine Biopharma, expressed satisfaction with the approval of Anastrozole, highlighting its importance for the company's generics portfolio and commitment to affordable medicines.
Sunshine Biopharma: Sunshine Biopharma received Canadian regulatory approval for its generic Anastrozole tablets, expanding its portfolio in breast cancer therapy and strengthening its position in the generics market. This approval is expected to contribute to its financial growth.
Jun 25, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how Steve N. Slilaty and Sunshine Biopharma interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.